This Article Full Text Full Text (PDF) Other Versions of this Article: CVI.00260-07v1 15/4/675    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Google Scholar Articles by Görander, S. Articles by Liljeqvist, J.-A. PubMed PubMed Citation Articles by Görander, S. Articles by Liljeqvist, J.-A.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, April 2008, p. 675-680, Vol. 15, No. 4
1071-412X/08/$08.00+0     doi:10.1128/CVI.00260-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Seroprevalences of Herpes Simplex Virus Type 2, Five Oncogenic Human Papillomaviruses, and Chlamydia trachomatis in Katowice, Poland

Departments of Virology,¹ Medical Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, Göteborg University, S-413 46 Göteborg, Sweden,² Department of Medical Microbiology, Medical University of Silesia, Katowice, Poland,³ Johns Hopkins University School of Medicine, Baltimore, Maryland⁴

Received 26 June 2007/ Returned for modification 31 October 2007/ Accepted 7 February 2008

Herpes simplex virus type 2 (HSV-2), human papillomaviruses (HPVs), and Chlamydia trachomatis are the most common pathogens causing sexually transmitted infections (STIs). There is limited information about the prevalences of these STIs in Poland. Here, we estimated the occurrence of immunoglobulin G (IgG) antibodies against HSV-2, HPV, and C. trachomatis in 199 blood donors and 110 patients of both genders attending an STI clinic in Katowice in southern Poland. The seroprevalences of HSV-2 were 5% for blood donors and 14% in the STI cohort. The seroprevalences of the five potentially oncogenic HPV types 16, 18, 31, 35, and 51 were 15%, 7%, 5%, 5%, and 17%, respectively, in blood donors and 37%, 8%, 12%, 5%, and 21%, respectively, in the STI cohort. The majority of HPV-infected individuals showed antibodies against more than one type, i.e., had been infected with multiple HPV types. Anti-C. trachomatis IgG antibodies were detected in 6% of blood donors and 13% of individuals attending the STI clinic. The relatively high prevalence of HPV-51 may have implications for future vaccine programs, as the newly introduced HPV vaccines are based on the potentially oncogenic HPV types 16 and 18.

Published ahead of print on 20 February 2008.